The first oral GLP-1 for weight management is here. How does it compare? On December 22, 2025, the FDA approved the Wegovy pill — the first oral GLP-1 medication for weight loss. Both the pill and injection contain semaglutide. Here's what the clinical data shows about each formulation.
Both the Wegovy pill and Wegovy injection contain the same active ingredient — semaglutide. The difference is in how it's delivered: a daily pill you swallow, or a weekly injection you administer. Clinical trials show comparable weight loss results with both formulations.
| Feature | Wegovy® pill | Wegovy® injection |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Formulation | Oral tablet (25mg) | Subcutaneous injection (2.4mg) |
| Frequency | Once daily | Once weekly |
| FDA approved | December 2025 | June 2021 |
| Key clinical trial | OASIS 4 | STEP 1 |
| Trial participants | 307 | 1,961 |
| Trial duration | 64 weeks | 68 weeks |
| Avg weight loss (adherent) | ~16.6% | ~14.9% |
| Avg weight loss (all participants) | ~13.6% | ~12.4% |
| Refrigeration required | No | Yes (36-46°F) |
| Administration | Swallow with water, empty stomach | Inject into abdomen, thigh, or upper arm |
| Waiting period | 30 min before eating/drinking | None |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Starting dose price* | ~$149/month (savings offer) | Varies by dose and insurance |
*Prices shown are approximate and reflect published list prices or savings offers. Actual costs vary based on insurance, pharmacy, and available programs. Clinical trial results from OASIS 4 (pill) and STEP 1 (injection) — separate trials with different populations, not directly comparable.
The Wegovy pill and injection were studied in separate clinical trials with different participant populations. While the results are similar, they cannot be directly compared head-to-head.
| Trial | OASIS 4 (pill) | STEP 1 (injection) |
|---|---|---|
| Participants | 307 | 1,961 |
| Duration | 64 weeks | 68 weeks |
| Avg weight loss (adherent) | 16.6% | ~14.9% |
| Avg weight loss (all) | 13.6% | ~12.4% |
| Placebo weight loss | 2.4% | 2.4% |
| ≥20% weight loss | 1 in 3 participants | ~1 in 3 participants |
| Published | The New England Journal of Medicine, September 2025. Wharton S, Lingvay I, et al. DOI: 10.1056/NEJMoa2500969 | The New England Journal of Medicine, February 2021. Wilding JPH, Batterham RL, et al. DOI: 10.1056/NEJMoa2032183 |
In March 2026, the FDA also approved Wegovy HD — a higher-dose 7.2mg injection for adults. This provides an additional injectable option with the potential for greater weight loss than the standard 2.4mg dose. The safety profile is consistent with existing semaglutide data.
Source: FDA press release, March 19, 2026. Approved under the National Priority Voucher program.
Only your healthcare provider can determine which formulation of Wegovy — pill, standard injection, or the new HD injection — is appropriate for your individual health needs, lifestyle, and medical history. This page presents published clinical data to help inform your conversation with your doctor.
Whether you take the pill or the injection, Dose AI helps you track your medication, nutrition, weight, and progress — all in one app.
Clinical trials show comparable results. The OASIS 4 trial showed 16.6% average weight loss with the pill (among adherent participants over 64 weeks), while the STEP 1 trial showed approximately 14.9% with the injection (over 68 weeks). However, these were separate trials and cannot be directly compared. Novo Nordisk states the pill delivers "similar" weight loss to the injection.
The Wegovy pill was FDA-approved on December 22, 2025. It became the first oral GLP-1 medication approved for weight management. It launched in US pharmacies in early January 2026.
The starting dose launched at approximately $149 per month through Novo Nordisk savings offers. Costs vary significantly based on insurance coverage, pharmacy, and available savings programs. Contact your pharmacy and insurance provider for your specific cost.
According to the manufacturer, some patients on Wegovy injection 2.4mg may be able to switch to the pill after stopping the injection and waiting one week. Any medication changes should be managed by your prescribing healthcare provider.
Take once daily on an empty stomach with a small sip of water (no more than 4 ounces). Wait at least 30 minutes before eating, drinking, or taking other medications. This ensures proper absorption. Follow your healthcare provider's instructions.
No. Unlike the injection, the Wegovy pill does not require refrigeration, making it more convenient for travel and daily life.
The most common side effects are gastrointestinal — nausea, diarrhea, and vomiting — similar to the injection. The OASIS 4 trial confirmed the safety profile is comparable to previous semaglutide trials. Discuss potential side effects with your doctor.
Yes. Dose AI tracks any GLP-1 medication, including both the Wegovy pill and injection. The app helps you log your daily medication, track weight progress, monitor nutrition, and stay consistent with your treatment.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making any decisions about your health or medications.
